Cereno Scientific secures loan of SEK 90 million, extending the company's financial runway into 2025 and strengthening partnership opportunities
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular diseases, announced today that the Board of Directors of Cereno Scientific has decided to enter into a loan agreement for the total amount of SEK 90 million (the "Loan") issued by Formue Nord Fokus A/S (the "Lender").Background and rationale for the Loan Cereno believes that, with its extensive experience in drug development, strong expert networks, and collaborative partnerships, the company has a significant opportunity to completely transform the treatment of